Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
Jorge Cortes, Alexander E. Perl, Hartmut Döhner, Hagop Kantarjian, Giovanni Martinelli, Tibor Kovacsovics, Philippe Rousselot, Björn Steffen, Hervé Dombret, Elihu Estey, Stephen Strickland, Jessica K. Altman, Claudia D. Baldus, Alan Burnett, Alwin Krämer, Nigel Russell, Neil P. Shah, Catherine C. Smith, Eunice S. Wang, Norbert IfrahGuy Gammon, Denise Trone, Deborah Lazzaretto, Mark Levis
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial'. Together they form a unique fingerprint.